All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

pristinamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	3489	270076-60-3

Description:

Molecule	Description
Synonyms: pristinamycine pristinamycin	An antibiotic mixture originally isolated from Streptomyces pristinaspiralis. It is a mixture of compounds from STREPTOGRAMIN GROUP A: pristinamycin IIA and IIB and from STREPTOGRAMIN GROUP B: pristinamycin IA, pristinamycin IB, pristinamycin IC. Molecular weight: 1349.51 Formula: C71H84N10O17 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 224.72 ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	109.35	42.47	36	1481	27345	63460160
Acute kidney injury	87.16	42.47	62	1455	263353	63224152
Rash maculo-papular	81.23	42.47	30	1487	31866	63455639
Acute generalised exanthematous pustulosis	75.63	42.47	22	1495	11077	63476428
Lactic acidosis	68.95	42.47	28	1489	38259	63449246
Cholestasis	68.78	42.47	26	1491	29408	63458097
Dermatitis exfoliative generalised	61.75	42.47	15	1502	3792	63483713
Hyperkalaemia	53.48	42.47	26	1491	54177	63433328
Drug reaction with eosinophilia and systemic symptoms	45.10	42.47	20	1497	33816	63453689

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urethritis mycoplasmal	50.11	41.22	6	756	18	34956151

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	136.25	37.16	50	2045	47543	79694750
Acute kidney injury	104.60	37.16	95	2000	519309	79222984
Rash maculo-papular	90.58	37.16	39	2056	56039	79686254
Acute generalised exanthematous pustulosis	79.89	37.16	26	2069	17228	79725065
Cholestasis	76.84	37.16	34	2061	52075	79690218
Lactic acidosis	52.86	37.16	29	2066	70330	79671963
Dermatitis exfoliative generalised	50.76	37.16	15	2080	7226	79735067
Urethritis mycoplasmal	48.97	37.16	6	2089	18	79742275
Eosinophilia	43.45	37.16	22	2073	45323	79696970
Hyperkalaemia	42.20	37.16	30	2065	114368	79627925
Drug reaction with eosinophilia and systemic symptoms	41.52	37.16	24	2071	64220	79678073
Myoglobin blood increased	38.05	37.16	10	2085	3141	79739152

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01FG01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Streptogramins
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
N0000170360	NUI
C1148067	UMLSCUI
CHEBI:85274	CHEBI
CHEMBL2146161	ChEMBL_ID
CHEMBL1256399	ChEMBL_ID
D025762	MESH_DESCRIPTOR_UI
DB13704	DRUGBANK_ID
1258	INN_ID
4O8O7Q7IU4	UNII
127053480	PUBCHEM_CID
66958	RXNORM
005720	NDDF

Pharmaceutical products:

None